Aldeyra Therapeutics Is Severely Undervalued Before PDUFA

My last Aldeyra (NASDAQ: ALDX ) article from September 2023 didn’t age well because, despite my positive coverage, ALDX stock crashed within a month on the news that the FDA would not approve reproxalap’s NDA for dry eye disease in itsAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material ...